You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for DROSPIRENONE-EE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DROSPIRENONE-EE

Average Pharmacy Cost for DROSPIRENONE-EE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
DROSPIRENONE-EE 3-0.02 MG TAB 31722-0934-31 0.14233 EACH 2025-01-22
DROSPIRENONE-EE 3-0.02 MG TAB 00378-7299-85 0.14233 EACH 2025-01-22
DROSPIRENONE-EE 3-0.03 MG TAB 75834-0115-84 0.16084 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Drospirenone-Ethinylestradiol (Drospirenone-EE)

Introduction to Drospirenone-Ethinylestradiol

Drospirenone and ethinylestradiol, commonly known as Drospirenone-EE, is a combination hormonal contraceptive used for various applications including birth control, moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea. This medication is available under several brand names such as Yaz, Yasmin, Ocella, and Loryna.

Market Size and Growth Projections

The Drospirenone and Ethinylestradiol Tablets Market is expected to experience significant growth over the forecast period. As of 2023, the market was valued at $25 billion and is projected to reach $45 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8%[1].

Global Contraceptive Drugs Market Context

The broader contraceptive drugs market, within which Drospirenone-EE falls, was valued at $18.57 billion in 2023 and is expected to grow to $37.22 billion by 2032, with a CAGR of 8.2% during the forecast period of 2024-2032. The oral segment, which includes Drospirenone-EE, dominates this market due to its higher adoption rates and clinical benefits[3].

Applications and Benefits

Drospirenone-EE is not only used for birth control but also offers several other benefits. It can help reduce menstrual cramps, bloating, and other premenstrual symptoms. Additionally, it may regulate menstrual cycles and reduce the risk of endometrial and ovarian cancer, as well as some forms of acne[4].

Pricing and Cost Considerations

The cost of Drospirenone-EE can vary depending on the pharmacy and the specific formulation. For instance, a supply of 28 tablets of the 3 mg-0.03 mg formulation can cost around $30, with prices ranging from $29.51 to $69.54 for different quantities[2].

Discounts and Assistance Programs

To make the medication more affordable, various discount programs and copay cards are available. For example, the Drugs.com Discount Card can save consumers up to 80% on prescription medications, including Drospirenone-EE. However, as of the latest data, there are no specific patient assistance programs available for this medication[2].

Market Segmentation

The Drospirenone and Ethinylestradiol Tablets Market is segmented based on type, application, and geography.

Type

  • The market includes various formulations of Drospirenone-EE, such as the 3 mg-0.02 mg and 3 mg-0.03 mg oral tablets[2].

Application

  • The primary applications include birth control, moderate acne, PMS, PMDD, and dysmenorrhea[1].

Geography

  • The market is analyzed at global, regional, and country levels. The Asia Pacific region is expected to register the highest CAGR during the forecast period due to increasing government initiatives and awareness about contraceptive drugs[1][3].

Key Players and Competitive Landscape

The market is dominated by several key players, including:

  • Camber Pharmaceuticals
  • Aurobindo Pharma
  • Teva Generics
  • Glenmark Pharmaceuticals
  • Xiromed
  • Wellona Pharma
  • Barr Pharmaceuticals, Inc.
  • Hetero Drugs
  • MYLAN LABS LTD.
  • Bayer Weimar GmbH und Co. KG[1].

These companies are evaluated based on their product offerings, financial statements, key developments, and strategic approaches to the market.

Regional Market Dynamics

North America

  • This region dominated the contraceptive drugs market in 2023, with a market size valued at $7.27 billion. The U.S. market is expected to grow significantly, driven by increasing consumer awareness and insurance coverage[3].

Asia Pacific

  • This region is anticipated to register the highest CAGR during the forecast period, driven by government initiatives and a surge in awareness about contraceptive drugs[3].

Latin America and Middle East & Africa

  • These regions also account for a significant share of the global market, with growth driven by government and organizational initiatives to increase awareness and access to contraceptive drugs[3].

Future Outlook and Trends

Increasing Demand for Oral Contraceptives

  • The oral segment of the contraceptive drugs market is expected to continue leading due to its ease of administration and higher adoption rates in both developed and developing countries[3].

Regulatory Approvals

  • Recent approvals, such as the FDA approval of Lupin’s Drospirenone tablets in November 2022, are expected to supplement market growth[3].

Public Awareness and Education

  • Increasing focus on public programs to create awareness about birth control and family planning is a key driver of the market[3].

Key Takeaways

  • The Drospirenone and Ethinylestradiol Tablets Market is projected to grow significantly, reaching $45 billion by 2031.
  • The medication offers multiple benefits beyond birth control, including reducing premenstrual symptoms and regulating menstrual cycles.
  • The cost of Drospirenone-EE varies, but discount programs and copay cards can make it more affordable.
  • Key players are focusing on strategic collaborations and product approvals to gain a competitive edge.
  • Regional dynamics, especially in the Asia Pacific, are driving market growth due to increased awareness and government initiatives.

FAQs

What are the primary applications of Drospirenone-Ethinylestradiol?

  • The primary applications include birth control, moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea[1].

How much does a supply of Drospirenone-Ethinylestradiol typically cost?

  • A supply of 28 tablets can cost around $30, depending on the pharmacy and the specific formulation[2].

Which regions are expected to drive the growth of the Drospirenone-Ethinylestradiol market?

  • The Asia Pacific region is expected to register the highest CAGR during the forecast period, followed by significant growth in North America, Latin America, and the Middle East & Africa[1][3].

What are the benefits of Drospirenone-Ethinylestradiol beyond birth control?

  • It can help reduce menstrual cramps, bloating, and other premenstrual symptoms, regulate menstrual cycles, and reduce the risk of endometrial and ovarian cancer, as well as some forms of acne[4].

Which companies are the major players in the Drospirenone-Ethinylestradiol market?

  • Major players include Camber Pharmaceuticals, Aurobindo Pharma, Teva Generics, Glenmark Pharmaceuticals, Xiromed, Wellona Pharma, Barr Pharmaceuticals, Inc., Hetero Drugs, MYLAN LABS LTD., and Bayer Weimar GmbH und Co. KG[1].

Are there any patient assistance programs available for Drospirenone-Ethinylestradiol?

  • As of the latest data, there are no specific patient assistance programs available for this medication, although discount cards and copay programs can help reduce costs[2].

Sources

  1. Verified Market Reports: Drospirenone and Ethinylestradiol Tablets Market Size[1].
  2. Drugs.com: Drospirenone/ethinyl estradiol Prices, Coupons, Copay Cards & Patient Assistance[2].
  3. Fortune Business Insights: Contraceptive Drugs Market Size, Share | Global Report, 2032[3].
  4. Mobility Foresights: Global Drospirenone And Ethinyl Estradiol Market 2024-2030[4].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.